Showing results (41-50 of 77) with videos related to
Sort By:
Pageof 8
Journal of Andrology|August 28, 2010
High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancerJoshua K Napora, Ryan G Short, Denis C Muller, et al.Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsEdward Sausville, Patricia Lorusso, Michael Carducci, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitorLisa J Green, Philip Marder, Chad Ray, et al.Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.Clinical Colorectal Cancer|January 7, 2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancerWells A Messersmith, Antonio Jimeno, Heather Jacene, et al.JCO Oncology Practice|December 3, 2019
Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical TrialLauren M Hamel, David W Dougherty, Terrance L Albrecht, et al.European Urology Focus|July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)Max Kates, Xiangying Chu, Noah Hahn, et al.Scientific Reports|February 1, 2024
Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivorsStephen G Gonsalves, Leorey N Saligan, Christopher M Bergeron, et al.Pageof 8